Kazia Therapeutics Ltd · NASDAQ:KZIA
Kazia Therapeutics — Corporate Update (September 2026)
21 slides from Kazia Therapeutics's corporate update, Sep 1, 2026
Slide 1: Beyond Inhibition. Reprogramming Cancer Control.
Beyond Inhibition. Reprogramming Cancer Control. Corporate Update Call September 1, 2026 NASDAQ: KZIA | X: @KaziaTx
Slide 2: Important Notice and Disclaimer
Important Notice and Disclaimer This presentation contains forward-looking statements, which can generally be identified as such by the use of words such as “may,” “will,” “estimate,” “future,” “forward,” “anticipate,” “plan,” “expect,” “explore,” “potential” or other similar words. Any statement de
Slide 3: Agenda
Agenda Paxalisib Overview Investment Framework New Data • Stage IV TNBC • HR+/HER2- Breast Cancer • Stage IIb/III TNBC • pMMR Colorectal Cancer Clinical Trial Expansions Investment Framework Recap Summary & Next Steps 2
Slide 4: Paxalisib Overview
Paxalisib Overview Brain-penetrant, oral, once daily small molecule dual PI3K/mTOR inhibitor with epigenetic and Asset Overview immunomodulatory activity Origin Discovered by Genentech (GDC-0084); In-licensed by Kazia Therapeutics Development Stage Clinical Advanced Breast Cancer (ABC, Phase 1), Gli
Slide 5: Kazia-Sponsored Clinical Phase 1b Study Overview
Paxalisib Kazia-Sponsored Clinical Phase 1b Study Overview Multi-center, open-label, randomized trial Arm B • Recurrent, unresectable or metastatic Paxalisib + Pembrolizumab / Chemotherapy (21-Day Cycle) TNBC Paxalisib 15mg QD + pembrolizumab 200mg + • Confirmed that tumors express PD-L1 with clinic
Slide 6: Investment Framework
Investment Framework Key elements underpinning our potential for value creation Early clinical validation creates multiple paths to significant value Stage IV TNBC clinical observations + potential expansion into >$40B of additional oncology markets 6/6 6/6 Extensive Preclinical Data & IP to Support
Slide 7: New Data: Stage IV TNBC Highlights
Paxalisib New Data: Stage IV TNBC Highlights Translational evidence in 6/6 evaluable patients: paxalisib targeting CTC clusters and terminally exhausted T cells Early disruption of CTC clusters by paxalisib combination treatment in Stage IV TNBC Paxalisib Baseline 3 wk 6 wk 3 wk 3 wk 2 wk 1 wk % Red
Slide 8: New Data: Stage IV TNBC Highlights (Cont.)
Paxalisib New Data: Stage IV TNBC Highlights (Cont.) Translational evidence: paxalisib combination reinvigorating the immune landscape Nanostring RNA profiling of PBMCs isolated from longitudinal patient bloods pre- and post-paxalisib treatment Increased cytotoxicity, IFNγ, DCs Increased antigen pre
Slide 9: New Data: Stage IV TNBC Highlights (Cont.)
Paxalisib New Data: Stage IV TNBC Highlights (Cont.) Early efficacy readout predicts complete metabolic response MAR 25, 2025 JUL 23, 2025 AUG 6, 2025 AUG 20, 2025 AUG 21, 2025 NOV 10, 2025 JAN 21, 2026* FEB 26, 2026 APR 15, 2026 AUG 4, 2026 PET Scan BLOOD BLOOD PET Scan PET Scan BLOOD BLOOD BLOOD P
Slide 10: New Data: Stage IV TNBC Individual Patient Responses
Paxalisib New Data: Stage IV TNBC Individual Patient Responses Patient Age Dose Disease Sites Response Time to Response 1 target lesion, left upper 1 61 30mg Partial ~5 months lobe of lung Lung, liver, bone, 2 47 30mg Partial ~3 months lymph node lesions 3 45 15mg 5 target lesions Partial ~3 months
Slide 11: Safety Profile Supports Continued Clinical Development
Paxalisib New Data: Stage IV TNBC Safety Profile Supports Continued Clinical Development 0 0 13 Paxalisib-Related Suspected Unexpected Serious Total SAEs Reported Serious Adverse Events (SAEs) Adverse Reactions (SUSARs) or • 1 patient had 1 SAE Significant Safety Issues (SSIs) • • 1 patient had 3 SA
Slide 12: New Data: Stage IV TNBC Highlights (Cont.)
Paxalisib New Data: Stage IV TNBC Highlights (Cont.) Clinical evidence: first-in-human signals from six evaluable patients 100% of evaluable patients (6/6) showed clinical benefit. Selective immune reinvigoration o Terminally exhausted CD8⁺ T cells reduced in 100% of evaluable patients (6/6) o Media
Slide 13: Advancing Paxalisib Programs
Paxalisib Advancing Paxalisib Programs One biological opportunity, multiple high-value markets HR+ / HER2- BREAST CANCER TNBC pMMR CRC Large population • Relapse • CNS disease Metastasis • Brain metastases • Immune Large population • Limited I/O response • escape • Recurrence Resistance • Major unme
Slide 14: HR+ / HER2- Innovation & Highlights
Paxalisib New Data: HR+ / HER2- Innovation & Highlights Key Highlights Scientific Evidence • Patent protected Paxalisib + Fulvestrant +/- CDK4/6 inhibitor reduces tumor burden without toxicity • Extensive preclinical safety and efficacy evidence supporting paxalisib in combination with standard of c
Slide 15: HR+ / HER2- Innovation & Highlights (Cont.)
Paxalisib New Data: HR+ / HER2- Innovation & Highlights (Cont.) Scientific Evidence Comparison of tumor growth inhibition following treatment with Gedatolisib and Paxalisib in combination with Fulvestrant + Palbociclib in the MCF7 HR⁺ xenograft model ↑23% ↑23% Inhibition 150 Fulvestrant+Palbociclib
Slide 16: Stage IIb/III TNBC Innovation & Highlights
Paxalisib New Data: Stage IIb/III TNBC Innovation & Highlights Key Highlights Scientific Evidence Establishment of a clinically relevant preclinical neoadjuvant / adjuvant 4T1 • Patent protected surgical model • Significant residual disease and local recurrence suppressed by paxalisib combination th
Slide 17: pMMR CRC Innovation & Highlights
Paxalisib New Data: pMMR CRC Innovation & Highlights Key Highlights Scientific Evidence • Patent protected Paxalisib monotherapy and αPD1 combination suppresses primary tumor burden in pMMR+ CRC preclinical models • 52% reduction in tumor burden with paxalisib as a single agent (p = 0.035), well tol
Slide 18: Clinical Trial Ready
Paxalisib Clinical Trial Ready HR+ / HER2- Breast Cancer Stage IIb / III TNBC pMMR CRC (in adjuvant, followed by neoadjuvant setting) Paxalisib + Fulvestrant + Palbociclib Paxalisib + Pembrolizumab + Capecitabine Paxalisib Monotherapy and Paxalisib + for pre-treated HR+ / HER2- for high-risk Stage I
Slide 19: Investment Framework Recap
Investment Framework Recap Key elements underpinning our potential for value creation Early clinical validation creates multiple paths to significant value Stage IV TNBC clinical observations + potential expansion into >$40B of additional oncology markets 6/6 6/6 Extensive Preclinical Data & IP to S
Slide 20: Summary & Next Steps
Paxalisib Summary & Next Steps Summary o Brain-penetrant dual pan-PI3K/mTOR inhibitor in development (Only 2% of small-molecule drugs are brain-penetrant) o Designed to be best-in-class pan-PI3K pathway inhibitor with modest mTOR activity (dual targeting required to inhibit cancer cell proliferation
Slide 21: www.kaziatx.com ir@kaziatx.com
www.kaziatx.com ir@kaziatx.com
Kazia Therapeutics — Corporate Update (September 2026) on 6ix